ArticlePsycho-oncology2020
Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data.
Article in Psycho-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study).Psychiatry and clinical neurosciences · 2024Trial
- Risk of Insomnia Disorder in Japanese Cancer Patients: A Matched Cohort Study Using Employer-Based Health Insurance Claims Data.Cancer medicine · 2026Article
- Incidence and temporal trends of depression and anxiety following cancer diagnosis in Japan: Insights from the LIFE study.International journal of cancer · 2026Article
- Article
- Impact of societal change on anesthesia practice in Japan.Journal of anesthesia · 2025Article
- Longitudinal association between posterior occlusal contact and dementia development in a large retrospective cohort study using a Japanese claims database.Scientific reports · 2024Article
- Factors associated with depressive symptoms among cancer patients: a nationwide cross-sectional study.BMC public health · 2024Article
- Article
- Association of depression phenotypes and antidepressant treatment with mortality due to cancer and other causes: a community-based cohort study.Frontiers in psychology · 2023Article
- Risk of major depressive disorder in adolescent and young adult cancer patients in Japan.Psycho-oncology · 2022Article
- Anxiety and depression risk in Taiwan women with breast cancer and cervical cancer.Frontiers in oncology · 2022Article
- Treatment of Major Depressive Disorder in Japanese Patients with Cancer: A Matched Cohort Study Using Employer-Based Health Insurance Claims Data.Clinical drug investigation · 2020Article
- Risk of major depressive disorder in Japanese cancer patients: A matched cohort study using employer-based health insurance claims data.Psycho-oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with cancer are at high risk of depression. However, the risk of major depressive disorder (MDD) after cancer diagnosis has not been studied in a population setting in Japan. This cohort study used a Japanese medical claims database to examine time to MDD in cancer patients and the risk of MDD (hazard ratio; HR) compared with matched cancer-free controls.
methodsPrimary endpoint was time to MDD (starting 6 months before cancer diagnosis) in adult (18-74 years) cancer patients; secondary endpoint was time to MDD (6 months before to 12 months after cancer diagnosis) in a matched cohort of cancer patients and cancer-free controls. Multivariate analyses were performed to determine HRs for all cancers and for each cancer site.
resultsOf 35 008 cancer patients (mean age, 53.3 years), 2201 (6.3%) were diagnosed with MDD within 66 months. Matched cancer patients (n = 30 372) had an elevated risk of MDD compared with cancer-free controls (n = 303 720; HR [95% confidence interval] 2.96 [2.77-3.16]). MDD risk was highest in patients with multiple cancers, pancreatic cancer, and brain cancer. Compared with middle-aged patients, risk was higher in patients <40 years old and lower in patients ≥65 years old; risk tended to be higher in women than in men.
conclusionsCompared with cancer-free individuals, Japanese patients with cancer, mostly <65 years old, had an almost threefold higher risk of developing MDD within 12 months of cancer diagnosis. Physicians should watch for MDD in cancer patients and treat when necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.